ADAM17 and COVID-19: These variants were used as instrument variables to examine the effect of circulating ADAM17 on COVID-19, with an average F-statistic of 90 and 30 for the extracellular and cytoplasmic domains, respectively (Table 1, Supplementary Table S2).